{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG002","value":"22"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"AEs, Non-small cell lung cancer (NSCLC)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG002","value":"7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"SAEs, Non-small cell lung cancer (NSCLC)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG002","value":"22"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"AEs, Melanoma"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG002","value":"8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"SAEs, Melanoma"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG002","value":"19"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"title":"AEs, Renal cell cancer (RCC)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG002","value":"5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"title":"SAEs, Renal cell cancer (RCC)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG002","value":"16"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"title":"AEs, Mesothelioma"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG002","value":"4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"title":"SAEs, Mesothelioma"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"title":"AEs, Triple negative breast cancer (TNBC)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"title":"SAEs, Triple negative breast cancer (TNBC)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"93"}],"units":"Participants"}],"description":"Number of participants with AEs and SAEs, including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as AEs. The number of participants with AEs and SAEs is reported for each tumor type.","groups":[{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients naïve to anti-PD-1/PD-L1","id":"OG000","title":"Phase 2: Naive - LAG525 400 mg Q3W + PDR001 300 mg Q3W"},{"description":"Combination LAG525 600 mg + PDR001 400 mg (Q4W/Q4W) in patients naïve to anti-PD-1/PD-L1","id":"OG001","title":"Phase 2: Naive - LAG525 600 mg Q4W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients pre-treated with anti-PD-1/PD-L1","id":"OG002","title":"Phase 2: Pre-treated - LAG525 400 mg Q3W + PDR001 300 mg Q3W"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All patients in phase 2 who received at least one full or partial dose of LAG525 or PDR001.","reportingStatus":"POSTED","timeFrame":"From first dose of study treatment until last dose of study treatment plus 30 days post treatment, assessed up to 2.7 years.","title":"Phase 2: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","type":"SECONDARY","unitOfMeasure":"Participants"}